End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
26.14
CNY
|
+5.45%
|
|
+16.13%
|
+11.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,290
|
59,156
|
31,812
|
13,870
|
15,324
|
16,936
|
-
|
Enterprise Value (EV)
1 |
3,290
|
59,156
|
31,812
|
13,870
|
15,324
|
16,936
|
16,936
|
P/E ratio
|
18.6
x
|
8.26
x
|
4.38
x
|
22.1
x
|
40.3
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.58
x
|
4.28
x
|
1.96
x
|
2.1
x
|
2.21
x
|
1.89
x
|
1.51
x
|
EV / Revenue
|
1.58
x
|
4.28
x
|
1.96
x
|
2.1
x
|
2.21
x
|
1.89
x
|
1.51
x
|
EV / EBITDA
|
11.2
x
|
6.95
x
|
3.51
x
|
24.5
x
|
13.2
x
|
12.4
x
|
8.87
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.23
x
|
6.35
x
|
2
x
|
-
|
0.96
x
|
1.01
x
|
0.94
x
|
Nbr of stocks (in thousands)
|
535,409
|
633,250
|
660,007
|
659,552
|
656,003
|
647,894
|
-
|
Reference price
2 |
6.144
|
93.42
|
48.20
|
21.03
|
23.36
|
26.14
|
26.14
|
Announcement Date
|
3/13/20
|
3/15/21
|
4/28/22
|
4/27/23
|
4/23/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2,083
|
13,837
|
16,240
|
6,614
|
6,919
|
8,962
|
11,186
|
EBITDA
1 |
295
|
8,509
|
9,056
|
566.3
|
1,159
|
1,364
|
1,910
|
EBIT
1 |
202.5
|
8,369
|
8,689
|
707.2
|
439
|
978
|
1,508
|
Operating Margin
|
9.72%
|
60.48%
|
53.5%
|
10.69%
|
6.34%
|
10.91%
|
13.48%
|
Earnings before Tax (EBT)
1 |
203.3
|
8,347
|
8,649
|
704.4
|
442.8
|
976
|
1,505
|
Net income
1 |
178.3
|
7,007
|
7,430
|
629.1
|
383
|
864
|
1,333
|
Net margin
|
8.56%
|
50.64%
|
45.75%
|
9.51%
|
5.54%
|
9.64%
|
11.92%
|
EPS
|
0.3296
|
11.31
|
11.00
|
0.9500
|
0.5800
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/15/21
|
4/28/22
|
4/27/23
|
4/23/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
13.1%
|
132%
|
59.6%
|
3.94%
|
2.4%
|
5.1%
|
7.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
2.99%
|
-
|
3.3%
|
4.8%
|
Assets
1 |
-
|
-
|
-
|
21,052
|
-
|
26,182
|
27,771
|
Book Value Per Share
2 |
2.760
|
14.70
|
24.00
|
-
|
24.40
|
25.80
|
27.70
|
Cash Flow per Share
|
0.6200
|
13.50
|
13.20
|
-
|
-
|
-
|
-
|
Capex
1 |
537
|
2,889
|
5,438
|
1,648
|
1,422
|
400
|
400
|
Capex / Sales
|
25.76%
|
20.88%
|
33.49%
|
24.92%
|
20.55%
|
4.46%
|
3.58%
|
Announcement Date
|
3/13/20
|
3/15/21
|
4/28/22
|
4/27/23
|
4/23/24
|
-
|
-
|
Last Close Price
26.14
CNY Average target price
30
CNY Spread / Average Target +14.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.90% | 2.34B | | +11.84% | 27.79B | | -32.98% | 2.98B | | -15.97% | 2.52B | | -1.11% | 1.91B | | -13.37% | 1.83B | | -7.78% | 1.39B | | -0.38% | 1.27B | | +13.51% | 1.12B | | +4.01% | 1.13B |
Medical Supplies
|